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While neurons have long been considered the major player in multiple brain functions
such as perception, emotion, and memory, glial cells have been relegated to a far lesser
position, acting as merely a “glue” to support neurons. Multiple lines of recent evidence,
however, have revealed that glial cells such as oligodendrocytes, astrocytes, and
microglia, substantially impact on neuronal function and activities and are significantly
involved in the underlying pathobiology of psychiatric disorders. Indeed, a growing body
of evidence indicates that glial cells interact extensively with neurons both chemically
(e.g., through neurotransmitters, neurotrophic factors, and cytokines) and physically
(e.g., through gap junctions), supporting a role for these cells as likely significant
modifiers not only of neural function in brain development but also disease pathobiology.
Since questions have lingered as to whether glial dysfunction plays a primary role in the
biology of neuropsychiatric disorders or a role related solely to their support of neuronal
physiology in these diseases, informative and predictive animal models have been
developed over the last decade. In this article, we review recent findings uncovered using
glia-specific genetically modified mice with which we can evaluate both the causation of
glia dysfunction and its potential role in neuropsychiatric disorders such as autism and
schizophrenia.
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Introduction
Glial cells are the non-excitable supporting cells of the central nervous system (CNS) and classi-
ﬁed mainly as oligodendrocytes, astrocytes, and microglia. These cells are typically smaller in size,
but can be far more numerous than neurons in certain brain regions such as the cerebral cor-
tex. Overall, the ratio between neurons, and glial cells in the human CNS is approximately 4:1
(Azevedo et al., 2009), with oligodendrocytes being the most abundant type of glial cells (75.6%),
followed by astrocytes (17.3%) and microglia (6.5%) in human male brains (Pelvig et al., 2008).
Glial cells clearly provide “support” for both cells such as neurons and structures such as blood
vessels, but also can function to increase action potential conduction velocity via saltatory con-
duction from one node of Ranvier to the next in myelinated axons, and also the response to
damage in the CNS via gliosis, a non-speciﬁc reactive change in glial cells associated with their
proliferation or hypertrophy. Convergent lines of evidence frommultiple studies in neuroimaging,
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postmortem brains, and genome-wide association studies
(GWAS) have revealed a wide range of white matter abnor-
malities in schizophrenia (Dwork et al., 2007; Bernstein et al.,
2015). Indeed, the implication of oligodendrocytes and myelin
in schizophrenia has come from analyses of postmortem brains
using microarray gene expression (Iwamoto et al., 2005; Katsel
et al., 2005), protein expression (Dracheva et al., 2006), electron
microscopic studies (Uranova et al., 2011), and neuroimaging
(Kubicki et al., 2007).
Astrocytes are regarded as neuronal partners since they hold
concerted cross-talk with neighboring neurons, which is crucial
for normal brain function. Astrocytes are able to sense neurogen-
esis, development, and maturation of brain circuits and neuronal
activity leading to both homeostatic changes and increased cel-
lular crosstalk (Wang and Bordey, 2008; Parpura et al., 2012).
The homeostatic responses of astrocytes includes increases in
metabolic activity, the synthesis of a neuronal preferred energy
substrate lactate, clearance of neurotransmitters and buﬀering of
extracellular K+ ions to name but a few (Kimelberg, 2007; Wang
and Bordey, 2008; Parpura and Verkhratsky, 2012). The existence
of bidirectional communication between astrocytes and neurons
during synaptic communication and function has been concep-
tualized as the “tripartite synapse” with its associated alterations
in neuron–glia cross talk (Newman, 2003; Perea et al., 2009).
Oligodendrocytes, the myelin forming cells of the CNS, have
a small round cell body and about 4–6 branching processes,
which can myelinate up to 60 axons depending on the diame-
ter (Miller, 2002). By ensheathing axons, mature oligodendro-
cytes provide critical insulation to facilitate axonal conduction
by increasing the resistance and reducing the eﬀective capaci-
tance of the axonal membrane, resulting in faster conduction
speed in myelinated axons compared to unmyelinated axons of
the same diameter. In addition, recent studies have provided
unique roles of oligodendrocytes, indicating that myelination of
the axons cannot only inﬂuence neuronal properties in ways not
previously considered, but also may be a key source of trophic
and metabolic support for maintaining axonal integrity (Nave,
2010).
Microglia function as not only members of the innate immune
system but also participate in synaptic modulation and matura-
tion, learning, and memory processes. Importantly, they extend
a broad network of ramiﬁed processes in the CNS parenchyma.
After an injury to the brain, microglia rapidly extend highly active
exploratory processes into the sites of injury without any corre-
sponding cell body movement, potentially establishing a barrier
between healthy and injured tissues in which microglia actively
and constantly interact with neurons and astrocytes and sur-
vey the local environment (Davalos et al., 2005; Nimmerjahn
et al., 2005). Moreover, microglia can directly regulate both
synaptic function and synaptic maintenance in the absence of
injury or neuroinﬂammation (Bessis et al., 2007; Wake et al.,
2009).
The focus of this review is to examine what is known
regarding the relationship between altered glial cell func-
tion and the pathobiology of psychiatric disorders, and
whether glial dysfunction can play a causative role. First,
we examine the monogenic disorder Rett syndrome (RTT)
and examine the mouse model harboring a mutant methyl-
CpG binding protein 2 (MeCP2) gene where neuronal and
glial biology have been extensively investigated (Table 1).
Subsequently, we examine several other mouse models
for schizophrenia (Table 2) and how glial cell function
or dysfunction contributes both to the phenotype and
pathophysiology.
TABLE 1 | Summary of mutant MeCP2 mouse models.
Genotype Phenotype Reference
MeCP2
MeCP2-deficiency astrocytes
MeCP2tm1.1Bird/+ mice
Reduced BDNF
Reduced IL-1β and IL-6
Hyper-activated p38MARK pathways
Abnormal neuronal dendritic neurodevelopment
Maezawa et al. (2009)
MeCP2-deficiency astrocyte in vitro co-culture MeCP2 is present in all glial cell types in normal brain
Abnormal neuronal dendritic neurodevelopment
Ballas et al. (2009)
In globally MecP2 deficit mice, re-expression of MeCP2
preferentially in astrocytes
Improved locomotion and anxiety level Restored
respiratory abnormalities
Lioy et al. (2011)
MeCP2-deficiency microglia
MeCP2tm1.1Bird/+ mice
Increased glutamate release
Increased neurotoxicity
Glutamate inhibitor, gap channel hemichannel blocker,
and glutamate receptor antagonist blocked the
neurotoxicity
Maezawa and Jin (2010)
Re-expression of MeCP2 in microglia in MeCP2 null mice Improved RTT-like phenotype Derecki et al. (2012)
MeCP2tm1.1Bird/+ and MecP2tm1.1Jae mice Related phagocytic activity
Re-expression of MeCP2 in oligodendrocytes in MeCP2 null mice Milder RTT-like phenotype Nguyen et al. (2013)
MeCP2loxJ/y/NRG2Cre mice Mildly prolonging their life span
Significantly improved the locomotor deficits and
hindlimb clasping both in male and female
Fully restored the body weight
PLP and MBP remain reducing
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TABLE 2 | Summary of mutant DISC1, neuregulin-ErbB signaling mouse models, and others.
Genotype Phenotype Reference
DISC1
DISC1-deficiency astrocyte Diminished production of D-serine Ma et al. (2013)
B6.Cg-Tg(GFAP-tTA) 110Pop/J mice Abnormal behavior similar to schizophrenia
Increased sensitivity to NMDA antagonist and he ameliorative effects of
D-serine
DISC1-increased or decreased expression
oligodendrocyte
Knockdown of DISC1 increased oligodendrocytes differentiation
DISC1 overexpression decreased oligodendrocytes differentiation
Hattori et al. (2014)
DBZ-decreased expression oligodendrocyte
DBZ KO mice
Myelination in the corpus callosum was delayed but is mostly recovered
by adulthood
Oligodendrocytes with immature structural features were more
abundant
Shimizu et al. (2014)
Neuregulin-ErbB signaling
Astrocyte specific disruption of synCAM1
signaling
Increased locomotor activity in the dark period that are attenuated by
the psychostimulant D,L-amphetamine
Sandau et al. (2012)
GFAP-DNSynCAM1 mice Exhibited attenuation of changes in diurnal rhythm activity
Reduced anxiety levels
Reduced the acoustic startle paradigm
Neuregulin-ErbB4 receptor
signaling-deficiency oligodendrocyte
Myelin sheath is significantly thinner and
OLs morphology is less complex
Roy et al. (2007)
CNP-DNErbB4 mice Heightened anxiety and had an abnormal behavior
Enhanced sensitization to amphetamine
Altered dopamine signaling including levels of DAT and D1-like receptor
binding
Neuregulin-ErbB3 receptor
Signaling-deficiency oligodendrocyte
PLP/CreERT-ErbB3flox/flox mice
Deletion of selective ErbB3 receptor in oligodendrocytes
Deficits in social interaction and working memory
Makinodan et al. (2012)
Others
Mice with proteolipid protein overexpression
plpltg/− mice
The myelin was intact at the 2 months of age, but developed
demyelination
Reduced conduction velocity
Tanaka et al. (2009)
Increased anxiety
Spatial learning deficits and working memory deficits
Nogo-A knock out mice Sensorimotor deficit Willi et al. (2010)
Nogo-A−/− mice Motor stimulant response to systemic amphetamine
Increased dopamine D2 receptor expression in the striatal and limbic
regions
Selective overexpression of heme
oxygenase-1 (HO-1) in astrocytes
Hyperdopaminergic tone in the nigrostriatal and mesolimbic systems Song et al. (2012)
HMOX1 transgenic mice Sensorimotor deficit
MeCP2
Rett syndrome is currently considered a severe neurode-
velopmental disorder caused by sporadic mutations in the
X-chromosome-linked gene MeCP2 (Amir et al., 1999). Females
born with RTT develop normally for 6–18 months and then
begin to regress, losing speech, motor skills, and purposeful hand
motions and suﬀering other severe problems including men-
tal retardation, epileptic seizures, and overall retarded growth
(Hagberg, 2002). In fact, RTT brain shares certain features with
regressive type autism including small neuronal size, as well
as reduced dendritic branching and spines in selected regions
(Zoghbi, 2003; Armstrong, 2005).
MeCP2 Knockout Mice
In fact, male MeCP2 null mice show severe neurological symp-
toms at approximately 6 weeks of age, while heterozygous
female mice also develop behavioral symptoms after several
months (Guy et al., 2001). Loss of MeCP2 function in RTT
mice leads to abnormalities in dendritic arborization (Armstrong,
2005), basal synaptic transmission (Moretti et al., 2006), exci-
tatory synaptic plasticity (Asaka et al., 2006; Moretti et al.,
2006; Chao et al., 2007) and reduced spontaneous cortical
activity (Dani et al., 2005). Studies utilizing a mouse line
with a conditional MeCP2 gene knockout speciﬁc to neural
stem/progenitor cells, (nestin-Cre/MeCP2-/y) identiﬁed pheno-
types that resemble some of the symptoms of RTT-like phe-
notypes (Chen et al., 2001; Guy et al., 2001). However, mice
carrying a conditional knockout of MeCP2 in post-mitotic neu-
rons driven by the calcium/calmodulin-dependent protein kinase
2 (Camk2)-cre transgene (CamkII-Cre/MeCP2-/y; Chen et al.,
2001) exhibit milder and delayed RTT-like phenotypes com-
pared with the nestin-cre driven transgenic mice (Chen et al.,
2001). While the neurological symptoms of MeCP2 knockout
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mice are reversed by restoring MeCP2 expression (Guy et al.,
2007), normal MeCP2 expression in neuronal cells is unable
to prevent the phenotypes of the MeCP2 null mice (Alvarez-
Saavedra et al., 2007), which implicates the speciﬁc loss of glial
MeCP2 expression in the pathobiology of RTT. Thus, while
MeCP2 is widely expressed throughout various cell types in the
normal brain including neurons, and all types of glial cell such as
astrocytes, oligodendrocytes, and microglia (Ballas et al., 2009), it
appears plausible that while neuronal dysfunction was formerly
viewed as a signiﬁcant contributor to RTT causation, glial dys-
function actually may play a greater role in the development
of RTT.
MeCP2-Deficiency in Astrocytes
With the loss of MeCP2 expression in astrocytes, there are
signiﬁcant abnormalities in the expression of brain-derived neu-
rotrophic factor (BDNF); an established target of MeCP2 bind-
ing (Chang et al., 2006). Interestingly, astrocytes are known
to be involved in the initiation and regulation of nervous sys-
tem immune responses through the release of proinﬂammatory
cytokines (Farina et al., 2007), and it is noteworthy that the
expression of interleukin (IL)-1β and IL-6 in response to admin-
istration of lipopolysaccharide is reduced in this model compared
to that of controls. In addition, p38 mitogen activated protein
kinases (MARK) pathways are hyper-activated in this model
irrespective of exposure to lipopolysaccharide.
A prominent neuropathological feature associated with brains
of RTT is small neuronal size and reduction in dendritic branch-
ing and spine density (Armstrong, 2005). Since neurons with
more extensive contact with astrocytes promote more extensive
dendritic growth (van den Pol and Spencer, 2000), co-culture
experiments using intact neurons and astrocytes with MeCP2
deﬁciency were performed. In this study, neurons cultured in the
presence of the MeCP2 deﬁcient astrocytes displayed a much less
developed dendritic arborization than did neurons cultured with
wild type astrocytes (Ballas et al., 2009). Furthermore, the engi-
neered re-expression ofMeCP2 in astrocytes in vivomousemodel
led to both signiﬁcantly improved locomotion and anxiety levels
as well as respiratory state (Maezawa et al., 2009; Lioy et al., 2011).
MeCP2 Deficiency in Oligodendrocytes
When mice were engineered that lacked MeCP2 expression
in oligodendrocytes, they showed a normal lifespan and the
symptoms associated with the RTT-like phenotype commenced
at ∼10 weeks of age and were milder than those of MeCP2 null
mice where the symptoms typically began at 4–5 weeks of age
(Chen et al., 2001). With the observational phenotypic scoring
system (score = 0–10) considering ﬁve typical RTT phenotypic
traits such as mobility, gait, hindlimb clasping, tremors, and gen-
eral conditions (Guy et al., 2007; Nguyen et al., 2012), while
MeCP2 null mice reached a score of 6–10 between 9 and 15 weeks
of age (Chen et al., 2001), oligodendrocyte MeCP2 knockout
mice reached a score of 2 at 20 weeks of age. Additionally,
these mice are more active and develop severe hindlimb clasping
phenotypes. Restoration of MeCP2 expression solely in cells of
the oligodendrocyte lineage in MeCP2 global null mice partially
reverses the RTT-like phenotypes associated with loss of MeCP2
such as diminished life span, locomotor deﬁcits, and hindlimb
clasping both in male and female, and fully restored normal
body weight. However, while MeCP2 expression in the oligoden-
drocyte lineage cells partially rescues the aberrant expression of
MBP protein, it does not aﬀect the expression of either 2′,3′-
cyclic-nucleotide-3′-phosphodiesterase (CNPase), myelin oligo-
dendrocyte glycoprotein (MOG), or myelin proteolipid protein
(PLP) (Nguyen et al., 2012).
MeCP2-Deficiency in Microglia
Activated microglia release a large amount of glutamate and
this microglial-associated neurotoxicity is mediated primarily
by NMDA receptor signaling (Takeuchi et al., 2005). In addi-
tion to glutamate, activated microglia release pro-inﬂammatory
cytokines such as IL-1β, IL-6, interferon (IFN)-γ, and tumor
necrosis factor (TNF-α), which also promote neuronal dam-
age (Sawada et al., 1989; Mizuno et al., 1994, 2003; Suzumura
et al., 1996). TNF-α secreted from activated microglia is a major
neurotoxic cytokine that induces neurodegeneration through
silencing of cell survival signals and caspase-dependent cas-
cades including promotion of signaling through Fas ligand (Greig
et al., 2004; Block and Hong, 2005). Neurons treated with con-
ditioned media from MeCP2 null microglia display damaged
dendrites and the concentration of glutamate in the media is ﬁve
time higher than that in control media. The blocking of both
microglial glutamate synthesis by a glutaminase inhibitor and
microglial glutamate release by a gap junction connexin32 (Cx32)
hemichannel blocker abolishes the neurotoxic activity as well as
the blocking of a glutamate receptor antagonist. These reports
indicate that aberrant glutaminase activity or Cx32 expression
in microglia is responsible for the increased production and
release of glutamate, potentially implicating these modulators
in the pathobiology of microglia-induced RTT-like symptoms
(Maezawa and Jin, 2010).
Introduction of Wild Type Microglia into the
MeCP2 Null Mouse
Allogeneic transplantation of wild type bone marrow into
irradiation-conditioned MeCP2 null mice led to the engraftment
of wild type microglia into the MeCP2 null brain parenchyma.
The lifespan of thesemice was signiﬁcantly extended as compared
with MeCP2 null mice that received either an autologous bone
marrow transplant or untreated MeCP2 null mice. Similarly,
body and brain weights of MeCP2-null mice recipients of wild
type bone marrow recovered approximately to the level seen
in wild type mice. And while the overall appearance, tremor,
and gait of MeCP2 null mice recipients of wild type bone mar-
row were improved, the hindlimb clasping phenotype was not
changed. Additionally, these mice exhibited signiﬁcantly reduced
numbers of apneic episodes and greatly reduced respiratory irreg-
ularities. Interestingly, these beneﬁts resulting from engraftment
with wild-type microglia were diminished when phagocytic activ-
ity was inhibited pharmacologically by using annexin V which
results in substantial blocking of phagocytic activities (Lu et al.,
2011; Derecki et al., 2012).
Thus, the focus of RTT studies using animal models has begun
to swing from only studying potential neuronal dysfunction to
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include interrogation of a role for glial dysfunction and the results
of the above studies lends credence to the hypothesis that glial
dysfunction may play a primary rather than a secondary role in
the causation of RTT-like symptoms. Similarly, studies of DISC1
knockout mice and neuregulin 1 (NRG1) knockout mice as mod-
els for schizophrenia initially focused on the role these proteins
play in neurons, but more recently, their activities in glial cells
have begun to be considered.
Disrupted in Schizophrenia 1 (DISC1)
Schizophrenia, which aﬀects ∼1% of the worldwide population,
is also known as a neurodevelopmental disorder (Weinberger,
1987). The clinical features of schizophrenia cluster in three
domains, characterized by positive symptoms (e.g., delusions,
hallucinations, thought disorder), negative symptoms (e.g., social
withdrawal, blunted aﬀect, reduced motivation) and cogni-
tive symptoms (e.g., attention and working memory deﬁcits).
Although schizophrenia is a complex disorder with polygenic
and environmental antecedents, multiple lines of evidence have
proposed some putative susceptibility genes for schizophrenia
(Harrison and Weinberger, 2005; Schizophrenia Working Group
of the Psychiatric Genomics, 2014). For example, two overlap-
ping and opposite strand genes on chromosome 1, DISC1 and
DISC2, are speciﬁcally disrupted by a t(1;11; q42.1; q14.3) bal-
anced translocation, in a large Scottish pedigree, resulting in a
cohort with several major mental illnesses such as schizophre-
nia, bipolar aﬀective disorder, and recurrent major depression (St
Clair et al., 1990; Millar et al., 2000, 2001; Blackwood et al., 2001;
Muir et al., 2008). DISC1 is expressed in neurons within various
brain areas including the olfactory bulb, cortex, hippocampus,
hypothalamus, cerebellum, and brain stem, especially during
development (Schurov et al., 2004). DISC1 has been shown to
be involved in several neurodevelopmental processes including
progenitor cell proliferation (Mao et al., 2009), radial migration
(Tomita et al., 2011), dendritic arborization (Kamiya et al., 2006;
Duan et al., 2007), and synapse formation (Camargo et al., 2007;
Duan et al., 2007).
DISC1 Knockout Mice
Since expression of dominant negative proteins frequently has
been used successfully in animal models to achieve partial loss
of function for relevant proteins (Oike et al., 1999), transgenic
mice harboring a C-terminally truncated, dominant negative
DISC1 (DN-DISC1), expressed under the control of a promoter
for αCaMKII, were generated (Hikida et al., 2007). This model
displays several abnormalities including hyperactivity, distur-
bance in sensorimotor gating, the dynamic modulation of reward
value by eﬀortful action, progressive ratio performance, social
behavior, and an anhedonia/depression-like deﬁcit (Hikida et al.,
2007; Pletnikov et al., 2008; Johnson et al., 2013). In distinction
from DN-DISC1 mice, N-ethyl-N-nitrosourea (ENU) was used
to induce mutations in exon 2 of mouse Disc1 gene, resulting in
the occurrence of missense mutations such as Q31L (glutamine
to leucine) or L100P (leucine to proline), causing an increase in
depression-like behaviors in Q31L mice and schizophrenia-like
behaviors including impaired prepulse inhibition (PPI) and latent
inhibition in L100P mice (Clapcote et al., 2007; Shoji et al., 2012).
Furthermore, the phenotypes of Q31L mutant mice were partly
improved with administration of an antidepressant. Thus, DISC1
dysfunction, likely can exert its inﬂuence on neuropsychiatric
disorders from its role in both neurons and glia.
An Increase or Decrease of DISC1
Expression in Oligodendrocytes
Expression of hDISC1 could exert a signiﬁcant inﬂuence
on oligodendrocyte proliferation, diﬀerentiation, and function
(Katsel et al., 2011). In fact, DISC1 is expressed in oligoden-
drocytes in the corpus callosum (Seshadri et al., 2010). In rat
oligodendrocyte precursor cell cultures (Hattori et al., 2014),
DISC1 expression decreases in the course of oligodendrocyte dif-
ferentiation. Furthermore, the expression of CNPase and myelin
basic protein (MBP) known to markers of myelin maturation
were decreased following full length DISC1 overexpression. In
contrast, the knockdown of endogenous DISC1 using RNA inter-
ference increased the expression of CNPase as well as the number
of mature oligodendrocytes (Hattori et al., 2014). SRY box con-
taining (Sox) family member, Sox10, the homeobox containing
(Hox) transcription factor Nkx2.2, the basic helix-loop-helix
(bHLH) family members Olig1 and Olig2 and the inhibitor of
DNA binding (Id) family of proteins Id2 and Id4 have all been
shown to be involved in the control of oligodendrocyte diﬀerenti-
ation (Nicolay et al., 2007; Emery, 2010). Against this backdrop, it
is perhaps not surprising that knockdown of DISC1 increased the
expression of Sox10 and/or Nkx2.2, and DISC1 overexpression
led to the reduced expression of these transcription factors. These
ﬁndings are strongly supportive of a role for DISC1 in negatively
regulating oligodendrocyte diﬀerentiation by acting upstream of
Sox10 and/or Nkx2.2 to regulate their transcription (Hattori et al.,
2014).
A Decrease of DBZ Expression in
Oligodendrocytes
DISC1 binding zinc ﬁnger protein (DBZ), also known as ZNF365
or Su48, is a CNS speciﬁc member of the DISC1 interactome
and is a novel DISC1 binding protein with a predicted C2H2-
type zinc-ﬁnger motif and coil domains (Hattori et al., 2007).
DBZ regulates neurite outgrowth via the DISC1-DBZ interac-
tion in primary neurons and cultured PC12 cells in vitro (Hattori
et al., 2007). In DBZ knockout mice, oligodendrocytes display-
ing an immature structural morphology are more abundant than
in control mice and the timing of myelination in the corpus cal-
losum is delayed (Koyama et al., 2013). Although this model
implicates DBZ function in oligodendrocyte development and
myelination, further studies using more speciﬁc models such
as oligodendrocyte-speciﬁc DBZ knockout mice are needed to
elucidate the precise function of DBZ (Shimizu et al., 2014).
DISC1-Deficiency in Astrocytes
Since the administration of the N-methyl-D-aspartic acid
(NMDA) receptor antagonists phencyclidine andMK-801 induce
behaviors that closely resemble those observed in schizophrenic
patients, dysfunction of the NMDA receptor is regarded as a
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particularly strong candidate for being a component of the mech-
anism of schizophrenia (Javitt and Zukin, 1991; Goﬀ and Coyle,
2001). The stereoisomer D-serine binds to the “glycine site” on the
NR1 subunit and it is crucial for the activation of this receptor.
D-serine acting as co-agonist at the NMDA receptor is involved
in synaptic plasticity (Fossat et al., 2012; Rosenberg et al., 2013),
and D-amino acid oxidase (DAAO) degrades the D-serine, mod-
ulating D-serine levels and thence NMDA receptor function
(Duplantier et al., 2009; Strick et al., 2011). The biosynthesis of D-
serine was clariﬁed by the puriﬁcation and molecular cloning of
serine racemase (SR), which transforms L-serine to D-serine, and,
interestingly, DISC1 binds to and stabilizes SR (Wolosker et al.,
1999a,b; De Miranda et al., 2000). Furthermore, D-serine and
SR have been predominantly localized to astrocytes ensheath-
ing synapses, especially in brain regions with enriched NMDA
receptors, suggesting that D-serine could be acting as a glial trans-
mitter (Puyal et al., 2006; Williams et al., 2006). In this model
of selective and inducible expression of mutant DISC1 in astro-
cytes, the expression of mutant DISC1 downregulates the level
of endogenous DISC1 expression in astrocytes. The disruption of
DISC1 binding to SR leads to increased ubiquitination and degra-
dation of SR in astrocytes. The decrease of SR in astrocytes results
in diminished production of D-serine in astrocytes. This mouse
model displays abnormal behaviors like schizophrenia including
sensitivity to an NMDA antagonist; MK-801, in an open ﬁeld test
and pre-pulse inhibition of acoustic startle test, and responds to
the ameliorative eﬀects of D-serine (Ma et al., 2013).
Neuregulin-ErbB Signaling
Neuregulins comprise a large family of widely expressed,
alternatively spliced epidermal growth factor (EGF)-like domain-
containing proteins that have been strongly implicated in neu-
ral development (Corfas et al., 2004; Mei and Xiong, 2008).
NRG proteins act by binding to and activating members of the
ErbB receptor tyrosine kinase family. After the initial discov-
ery of what came to be known as NRG1, ﬁve additional NRG1
homologs (NRG2, NRG3, NRG4, NRG5, and NRG6) have been
identiﬁed. NRG1 proteins bind only to either ErbB3 or ErbB4
causing a conformational change that promotes receptor dimer-
ization and auophosphorylation, and the subsequent activation
of downstream signaling pathways. However, NRG1 does not
bind to the ErbB2 receptor, which functions as a co-receptor
that heterodimerizes with ErbB3 or ErbB4. Additionally, ErbB4
is known to be able to function as a homodimer. In adult brains,
ErbB receptors are widely and diﬀerentially expressed. In gen-
eral, ErbB2 is expressed in most cells, ErbB3 is mainly found in
glial populations, and ErbB4 is enriched in neurons. NRG/ErbB
signaling has been widely implicated in psychiatric disorders
including schizophrenia, bipolar disorder, or depression (Corfas
et al., 2004; Mei and Nave, 2014).
Astrocyte Specific Disruption of synCAM1
Signaling
Synaptic cell adhesion molecule 1 (SynCAM1) is a member of
the immunoglobulin (Ig) superfamily, a large group of proteins
involved in cell surface recognition (Williams, 1992; Rougon and
Hobert, 2003). SynCAM1 plays an important role in CNS devel-
opmental processes such as synaptic assembly (Biederer et al.,
2002), enhancement of excitatory synaptic transmission (Sara
et al., 2005; Fogel et al., 2007), functional presynaptic diﬀeren-
tiation (Sara et al., 2005) and the regulation of synapse number
and plasticity (Robbins et al., 2010). SynCAM1 is produced
in astrocytes and plays a major role in facilitating astrocyte-
to-astrocyte and astrocyte-to-neuron adhesive communication
(Sandau et al., 2011). SynCAM1 is co-expressed with ErbB4 in
astrocytes (Sandau et al., 2011) and is functionally related to
ErbB4 receptors (Carpenter, 2003). Mice carrying a dominant-
negative form of SynCAM1, speciﬁcally targeted to astrocytes,
exhibited an attenuation of changes in diurnal rhythm activity.
In addition, the locomotor activity in a dark ﬁeld is increased
and it is attenuated with the psychostimulant D, L-amphetamine,
and anxiety is reduced in a zero maze test and an acoustic star-
tle paradigm in these mice. These ﬁndings imply that these mice
could be utilized as a model of neurodevelopmental disorder
(Sandau et al., 2012).
Neuregulin-ErbB4 Receptors
Signaling-Deficiency in Oligodendrocytes
Neuregulin 1-ErbB receptor signaling appears to play a critical
role in the ontogeny of psychiatric disorders and this hypoth-
esis has been supported by the identiﬁcation of altered expres-
sion levels and/or function of NRG1, ErbB3, and ErbB4 in
patients with schizophrenia (Corfas et al., 2004; Silberberg et al.,
2006). Moreover, mice with reduced levels of NRG1 or ErbB4
have exhibited behavioral alterations akin to those found in
schizophrenia (Gerlai et al., 2000; Golub et al., 2004; Rimer et al.,
2005).
Transgenic mice expressing a dominant-negative ErbB4
receptor in oligodendrocytes exhibit thinner myelin and less
complex oligodendrocyte morphology and show schizophrenia-
like behaviors including high anxiety and an enhanced sensitiza-
tion to amphetamine. This abnormal response to amphetamine
might be due to altered dopamine signaling as aberrant expres-
sions of dopamine transporter (DAT) and dopamine1-like recep-
tor in the cortex, nucleus accumbens, and striatum are evident
(Roy et al., 2007).
Neuregulin-ErbB3 Receptor
Signaling-Deficiency in Oligodendrocytes
Neuregulin 1-ErbB signaling plays, at least in part, a criti-
cal role in oligodendrocyte development and CNS myelination
(Michailov et al., 2004; Taveggia et al., 2005; Chen et al., 2006). In
human prefrontal cortex, microarray analyses revealed that the
level of ErbB3 was signiﬁcantly reduced in schizophrenia subjects
relative to a normal cohort (Hakak et al., 2001). This decre-
ment was reproduced by another study (Tkachev et al., 2003).
Consistent with the results of human studies, mice with selec-
tive ErbB3 receptor deletion in oligodendrocytes demonstrate
deﬁcits in social interaction and working memory (Makinodan
et al., 2012), suggesting that NRG1-ErbB3 signaling in oligoden-
drocyte might contribute to the pathogenesis of schizophrenia
(Makinodan et al., 2012).
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Other Studies
Mice with Proteolipid Protein
Overexpression
Proteolipid protein 1, a major protein in CNSmyelin (Inoue et al.,
1996; Mimault et al., 1999), is regarded as an “adhesive strut”
that binds adjacent lamellae of the compacted myelin membrane
(Boison et al., 1995).
Transgenic mice harboring extra copies of the myelin PLP1
gene have demonstrated that at the 2 months of age, the
myelin was intact with a normally appearing ion channel dis-
tribution (Inoue et al., 1996), whereas the conduction veloc-
ity in all axonal tracts tested in the CNS was markedly
reduced at this age (Tanaka et al., 2009). This observation
was supported by subsequent analysis that these mice showed
altered neuron–glia interaction with subtle changes in axonal
diameters and paranodal structures, leading to schizophrenia-
like behaviors including increased anxiety-related behaviors,
reduced PPI, spatial learning deﬁcits, and working memory
deﬁcits.
Nogo-A Knockout Mice
Nogo signaling plays a crucial role in restricting axonal regen-
eration and compensatory ﬁber growth in the injured adult
mammalian CNS (Schwab, 2004; Yiu and He, 2006). The mem-
brane protein Nogo-A, which is predominantly expressed in
oligodendrocytes in the adult brain and in neurons mainly
during development, is well-known for its role as one of sev-
eral currently known inhibitors of neurite outgrowth (Huber
et al., 2002; Wang et al., 2002). Postmortem and genetic stud-
ies have implicated Nogo-A and its choromosomal location in
schizophrenia and bipolar disorder (Coon et al., 1998; Novak
et al., 2002).
These mice showed sensorimotor deﬁcits, disrupted latent
inhibition, and perseverative behaviors. Furthermore, they dis-
played an enhanced response to systemic amphetamine in an
open ﬁeld test. These behavioral phenotypes might be due to
altered monoaminergic transmitter levels in the striatal and lim-
bic regions and/or increased dopamine D2 receptor expression in
the identical brain regions. In contrast, adult mice acutely treated
with anti-Nogo-A antibodies did not exhibit abnormal behaviors,
but showed increased dopamine D2 receptor expression (Willi
et al., 2010).
Selective Overexpression of Heme
Oxygenase-1 (HO-1) in Astrocytes
The heme oxygenases (HOs), which are responsible for the degra-
dation of heme to biliverdin/bilirubin, free iron and carbon
monoxide (CO), has been strongly implicated in mammalian
CNS aging and diseases (Schipper et al., 2009). Mammalian cells
express two isoforms such as an inducible isoform, HO-1, and
a constitutively active form, HO-2. Speciﬁcally, HO-1, encoded
by the HMOX1 gene, is a 32-kDa stress protein, and the induc-
tion of the glial HMOX1 gene may lead to pathological brain iron
deposition, intracellular oxidative damage, and bioenergetic fail-
ure in Alzheimer’s disease and other human CNS disorders such
as Parkinson’s disease and schizophrenia (Schipper et al., 2009;
Brown, 2011). This mice model displayed sensorimotor deﬁcits,
increased spontaneous horizontal movements, and stereotypy.
Hyperdopaminergic signaling was identiﬁed in the striatum and
substantia nigra and the associated neurochemical alterations
may contribute to these behaviors (Song et al., 2012).
Conclusion
In conclusion, studies leveraging diﬀerent animal models for
the enhanced biochemical and physiological understanding of
mental disorders have moved from strictly targeting the biol-
ogy of neurons to also include an examination of the glia,
especially since glial cells such as oligodendrocytes, astrocytes,
and microglia have emerged as critically important modiﬁers of
both CNS development and function. Postmortem brain analy-
ses have clearly indicated that glial cell abnormalities are present
in the brains of patients with schizophrenia. However, it remains
uncertain whether the dysregulation and symptoms seen are a
primary result of alterations in glial cell biology or the deﬁcits
in glial function occur as a side product of neuronal dysfunction.
Nonetheless, as we have described, continued use of cell-type spe-
ciﬁc conditional knockout mice will allow us to better dissect
how glial cells are implicated in nervous system dysfunction and
perhaps illuminate their role in the pathobiology of psychiatric
diseases such as schizophrenia.
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